OxyContin, first introduced by Purdue Pharma in 1996, was aggressively marketed to physicians, nurses and pharmacists as a superior, longer-lasting, and safer treatment for cancer-related chronic pain as well as other pain, and as a treatment for “non- malignant pain” (long-lasting pain with no identified precursor). The marketing campaign was intense even though randomized double-blind studies found that OxyContin was no more effective than opioids already in use for the treatment of pain. Purdue’s intense promotion of the drug proved to be very lucrative for the company. From the time of its introduction to 2000, a mere four years, sales of OxyContin grew from $48 million to over $1 billion.
Purdue Pharma claimed that the risk of addictionto the drug was minimal, maintaining that less than one percent of those that used the drug got addicted. The company even cited studies to confirm this “fact.” We know now that OxyContin is highly addictive; Purdue knew it then. OxyContin, zealously promoted and widely available, was a “gateway” drug to theopioid crisesthat continues to grip the country. Yet, Purdue Pharma claimed for years that it was unaware of OxyContin’s addictive properties. That was an outright lie.
A United States Justice Department investigation exposed conclusive evidence that Purdue was well aware of OxyContin’s addiction risks as early as 1997. Yet, when Purdue’s chief medical officer was called to testify before the House Appropriations subcommittee in 2001 concerning the then evident risks of OxyContin addiction abuse, he claimed that Purdue was unaware of the problem for the first four years it was on the market.